血管紧张素转换酶抑制剂或受体阻滞剂对急性肾损伤患者ICU出院后结局的影响
该观察性队列研究纳入21个欧洲ICU出院的1551例患者,探讨ICU出院时处方ACEi/ARB与1年全因死亡率的关系。急性肾损伤(AKI)按肾脏病改善全球结局定义,占611例(39%)。在AKI患者中,未调整、调整和倾向评分匹配的1年死亡率在出院时使用ACEi/ARB者中均更低(匹配HR 0.48,95%CI 0.27-0.85,p<0.001);无AKI患者中未观察到关联。作者结论认为,AKI后存活出ICU的患者出院时处方ACEi/ARB与1年死亡率降低相关。
要点
- 在AKI后存活出ICU的患者中,出院时处方ACEi/ARB与1年死亡率降低相关:倾向评分匹配HR 0.48(95%CI 0.27-0.85,p<0.001)。
- 未调整分析HR 0.55(95%CI 0.35-0.89),多因素调整后HR 0.45(95%CI 0.27-0.75),敏感性分析结果一致。
- 无AKI患者中未观察到ACEi/ARB处方与1年死亡率的关联。
- 整体1年死亡率:AKI患者28%(n=611,39%),无AKI患者15%(n=940)。
- 该研究为观察性队列,ACEi/ARB处方与结局的关联不能推断因果关系。
适用人群与场景
- 从21个欧洲ICU存活出院的患者,共1551例,其中AKI患者611例(39%),无AKI患者940例。
- AKI定义采用肾脏病改善全球结局(KDIGO)定义。
诊断标准与关键阈值
- AKI定义:肾脏病改善全球结局(kidney disease improvement global outcome)定义。
研究设计与关键结果
- 研究类型:观察性队列研究,纳入21个欧洲ICU出院的1551例患者。
- 主要终点:ICU出院后1年全因死亡率。
- 整体1年死亡率:AKI患者28%(n=611),无AKI患者15%(n=940)。
- AKI患者中,出院时使用ACEi/ARB者1年死亡率更低:未调整HR 0.55(95%CI 0.35-0.89),调整后HR 0.45(95%CI 0.27-0.75),倾向评分匹配HR 0.48(95%CI 0.27-0.85,p<0.001)。
- 敏感性分析结果一致。
- 无AKI患者中未观察到ACEi/ARB处方与1年死亡率的关联。
证据类型、等级与局限
- 证据类型:观察性队列研究。
- 倾向评分匹配模型纳入变量:慢性心力衰竭、ICU入科时使用ACEi/ARB、Charlson合并症指数、年龄、糖尿病、慢性肾脏病、估算肾小球滤过率、ICU出院时动脉血压、血管升压药使用和肾脏替代治疗。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在经历AKI后存活出ICU的患者中,出院时处方ACEi/ARB与1年死亡率降低相关。
- 该关联为观察性研究结果,原文未据此给出治疗推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Acute kidney injury (AKI) is associated with the activation of the renin-angiotensin system. Whether angiotensin-converting enzyme inhibitors (ACEi) or angiotensin-receptor blockers (ARB) improve outcome in patients recovering from AKI remains unexplored. The purpose was to investigate the association between prescription of ACEi/ARB at intensive care unit (ICU) discharge and 1-year outcome in patients recovering from AKI.
METHODS: Association between ACEi/ARB and 1-year mortality rate was explored in 1551 patients discharged from 21 European ICUs in an observational cohort. One-year all-cause mortality after ICU discharge was the primary endpoint. AKI was defined using the kidney disease improvement global outcome definition. Propensity score matching was used to consider the probability to receive ACEi/ARB at ICU discharge and included chronic heart failure, ACEi/ARB on ICU admission, Charlson Comorbidity Index, age, diabetes mellitus, chronic kidney disease, estimated glomerular filtration rate and arterial blood pressure at ICU discharge vasopressors and renal replacement therapy.
RESULTS: Overall, 1-year mortality was 28 and 15% in patients with AKI (n = 611, 39%) and without AKI (n = 940), respectively. In patients with AKI, unadjusted, adjusted and propensity-score matched 1-year mortality rates were lower in patients treated with ACEi/ARB at ICU discharge [HR of 0.55 (0.35-0.89), HR of 0.45 (0.27-0.75), and HR of 0.48 (0.27-0.85, p < 0.001), respectively]. These results were consistent across sensitivity analysis. No association was observed in patients without AKI.
CONCLUSIONS: In patients discharged alive from the ICU after experiencing AKI, ACEi/ARB prescription at discharge is associated with a decrease in 1-year mortality.
TRIAL REGISTRATION: ClinicalTrials.gov NCT01367093. Registered on 6 June 2011.
参考来源
- Gayat E, Hollinger A, Cariou A, et al. Impact of angiotensin-converting enzyme inhibitors or receptor blockers on post-ICU discharge outcome in patients with acute kidney injury. Intensive Care Med. 2018. PMID: 29766216. doi:10.1007/s00134-018-5160-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。